An Indian-origin woman who was given just months to live a few years ago is celebrating on Monday after doctors say she is showing no evidence of breast cancer following a clinical trial at a UK hospital.
The researchers believe their findings provide a blueprint for a second-generation, universal vaccine that could prevent infection from current and future SARS-CoV-2 variants, including Omicron.
Adults who stay well-hydrated appear to be healthier, develop fewer chronic conditions, such as heart and lung disease, and live longer than those who may not get sufficient fluids.
'...but subjecting our heritage to rigorous evidence-based understanding.'
'They are attacking my wife; they are attacking our 13-month-old daughter. They are saying that I do drugs.' 'I'm giving an open challenge to Mr Nawab Malik and Ms Sana Malik let's go to the labs and let's do the medical test of our family and your family.'
COVAXIN, developed by Hyderabad-based Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, has got the nod for human clinical trials from the Drug Controller General of India
Bharat Biotech recruited 13,000 participants for the Phase-3 clinical trial of Covaxin. This is one of the largest efficacy trials held in the country.
According to sources, so far only one traveller from Canada having symptoms of monkeypox infection had been isolated.
The Saveetha Institute of Medical and Technical Sciences. The Indian School of Mines, Dhanbad. Vinay Umarji explains why these two universities have made India proud.
Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 per cent efficacy against symptomatic disease and present no serious safety concerns.
Covaxin is being developed by Bharat Biotech jointly with the Indian Council of Medical Research (ICMR)- National Institute of Virology (NIV). The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers and it is the country's first and only Phase III efficacy study for a COVID-19 vaccine, a press release from the vaccine maker said on Saturday night.
In the university category, IISc stood first, followed by JNU and BHU.
The phase 3 trial findings indicate that Covaxin induces a robust antibody response with no severe vaccine-related adverse events or deaths reported among the trial participants, the authors of the study said.
The fact sheet also asked people to inform the vaccinator or a supervising official about their medical condition before taking the vaccine.
The US Food and Drug Administration had in February approved Johnson & Johnson's COVID-19 vaccine that works with just one dose for emergency use.
In a series of tweets after the Drugs Controller General of India (DCGI) approved Oxford's vaccine Covishield and Bharat Biotech's Covaxin for restricted emergency use, Modi said it will make every Indian proud that both the vaccines are made in India.
The preventive aspect of cancer is strengthened under comprehensive primary healthcare through the Ayushman Bharat Health and Wellness Centre scheme by the promotion of wellness activities and targeted communication at the community level.
Groundbreaking HIV researcher Dr Suniti Solomon, the first to bring to the world the prevalence of the infection in India in 1986 and one who successfully led research into the treatment of the deadly virus, passed away at her residence in Chennai on Tuesday.
This doctor couple put their faith in India. And in return India has put faith in them.
As India holds its breath for the Covid vaccination to be begin, Sudhir Bisht provides a quick checklist of what you must know about the vaccines that will be administered to citizens.
Speaking after virtually launching COVID-19 testing facilities in Noida, Mumbai and Kolkata, Modi said that in the fight against coronavirus, India has come to a point where it does not lack in awareness, its scientific data is expanding and resources are also increasing.
The Central Drugs Standard Control Organisation has granted restricted emergency use authorisation to two new vaccines and a drug for COVID-19, taking the number of preventives and treatments available in India to 12.
Times have changed, situations have changed, but the basic nature of superpower geo-politics remains the same and so also India's diplomacy -- call it non-alignment, strategic autonomy or neutrality; it all depends on the time scale, notes Rup Narayan Das.
The Ministry of Human Resource Development has released its ranking of national institutes for 2018.
The New York Times on Tuesday said Covaxin works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus. The antibodies attach to viral proteins, such as the so-called spike proteins that stud its surface.
Safety and Efficacy results from the final analysis will be available in June, and the final report will be submitted to a peer-reviewed publication.
The National Clinical Registry for COVID-19 will collect systematic data on clinical signs and symptoms, laboratory investigations, management protocols, the clinical course of COVID-19, disease spectrum and outcomes of patients.
Bharat Biotech's Covaxin has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and 65.2 per cent protection against the new Delta variant.
More than 10 million older adults aged 60 or over in India may have dementia, comparable to the prevalence rates for countries such as the US and the UK, according to a first-of-its-kind study.
The panel was informed that the economic impact of the second wave of viral infection was "asynchronous in its onset and wider in its spread particularly in rural hinterland", a source said.
The Centre on Saturday night announced that the probe into alleged irregularities in the medical entrance exam NEET will be handed over to the CBI for a comprehensive investigation.
Health Minister Harsh Vardhan said the COVID-19 vaccine will be available in the next few months and it is estimated that by July-August 400-500 million doses will be made available for 25-30 crore people.
Ahmedabad was the first stop in the PM's three city tour today, to personally review the vaccine development and manufacturing process in the country.
The number of people who have recuperated from the disease surged to 1,01,62,738 pushing the national COVID-19 recovery rate to 96.53 per cent.
The research revealed that coronaviruses and their hosts are engaged in an evolutionary arms race that promotes genetic variety in the virus.
'We must not compromise with the standard, the quality. We don't need to be the first to launch a drug but what we need is a Made in India vaccine that the entire world can rely on'
In phase I, the vaccine would be tested on 375 volunteers and the maximum of 100 of them would be from AIIMS.
The allocation for health ministry for 2017-18 is Rs 47,352.51 crore in comparison to allocation in 2016-17 of Rs 37,061.55 crore.
Responding to another question, Choubey said that the phase-I of clinical trials have revealed excellent safety of the two candidate vaccines indigenously developed by Bharat Biotech in collaboration with Indian Council of Medical Research and Cadila Healthcare Ltd, and now their immunogenicity testing is in progress. Their phase II clinical trials are ongoing.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances